^
Association details:
| Biomarker: | RPS6KB1 amplification |
|---|---|
| Cancer: | Melanoma |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment
Published date:
12/15/2020
Excerpt:
Next-generation sequencing (NGS) was performed using tumor specimens collected from 178 Asian patients with metastatic melanoma receiving CPIs….MYC and RPS6KB1 amplifications were associated with responsiveness to CPIs (P < 0.05).
DOI:
10.1016/j.esmoop.2020.100002
Source:
Title:
Molecular features for selecting Asian metastatic melanoma patients who benefit from check-point inhibitors.
Published date:
05/13/2020
Excerpt:
NRAS and TP53 mutation and NF2 deletion were significantly related to patients without the response to CPIs (p < 0.05). Meanwhile, MYC and RPS6KB1 amplification were found with those with the response (p < 0.05). The median progression free survival (PFS) to ICIS was 5.9 months (95% CI 3.8 - 8.05 months).
DOI:
10.1200/JCO.2020.38.15_suppl.e22011
